OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024

Liver cancer is the second leading cause of cancer related death in the world in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) is the most dominant form of liver cancer, accounting for approximately 85% of liver cancer cases. The prognosis of HCC is dependent on the stage of the disease at diagnosis. However, even with treatments such as surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease.

Key Questions Answered in this Report

Full Report Details at
- http://www.fastmr.com/prod/1134032_opportunityanalyzer.aspx?afid=301

* Nexavar, approved in 2007, is the only available targeted treatment option for patients with advanced HCC and has dominated the HCC market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) since its launch.
* The current late and early stage pipeline is very strong and diverse. Which drug will have the biggest impact on the market? What strategies are developers undertaking to overcome the high risk of clinical trial failure?
* Nexavar will lose patent protection within the forecast period. How will this impact the HCC market and will new market entries be able to stabilize the HCC market?

Key Report Findings

* The main driver of growth in the HCC market is the expected launch of second-line treatments for patients with advanced HCC. The market growth will be further supported by an increase in HCC incidence numbers due to a growing aging population as well as market-specific increase in risk factors.
* The biggest barrier for HCC is the patent expiry of Nexavar and expected introduction of generic sorafenib in the 7MM. The effect of this will be strongest in the US where it will have the largest impact on the HCC market. Further patent expiries will also have a negative impact on the HCC market.
* The largest unmet needs in HCC are more treatment options for patients with advanced HCC. First line as well as second line and beyond treatments are urgently needed to improve the treatability of these patients.

Report Scope

* Overview of HCC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
* Annualized HCC market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
* Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the HCC therapeutics market.
* Pipeline analysis: focus on the late-stage pipeline HCC drugs discussing emerging trends as well as overview of earlier phase drugs.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Gaucher Disease - Opportunity Analysis and Forecast to 2024
- OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update